drugset / Trial / NCT00140361
Efficacy of Sulphadoxine-pyrimethamine and Artemisinin-containing Combination Therapy for Malaria
Phase 4
Completed
390 enrolled
Centers for Disease Control and Prevention
United States Agency for International Development (USAID) · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
This is an ongoing monitoring activity of efficacy of sulfadoxine-pyrimethamine (SP), which is the current national treatment of choice for uncomplicated malaria in Tanzania, and a combination of SP and artesunate among children \< 5 years in 3 sites in rural Tanzania. Protocol was amended in 2004 to (1) include lumefantrine+artemether, the newly identified first-line treatment for malaria to be introduced into Tanzania in 2006; (2) on a limited basis, include adult patients; (3) extend follow-up to 28 days; (4) investigate whether treated bednets would reduce confounding by reinfection
Timeline
- Start
- 2000-01
- Primary completion
- 2008-01
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Artemether | Small molecule | — | — |
| Subject | Artesunate | Small molecule | — | — |
| Subject | lumefantrine | Small molecule | — | — |
| Subject | pyrimethamine | Small molecule | — | — |
| Subject | sulfadoxine | Small molecule | — | — |